NextCure (NASDAQ:NXTC) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of NextCure (NASDAQ:NXTC) in a research note published on Friday, Benzinga reports. They currently have a $8.00 price target on the stock.

Separately, Needham & Company LLC restated a buy rating and issued a $4.00 price objective on shares of NextCure in a research report on Wednesday, March 20th.

NextCure Price Performance

NXTC stock traded up $0.04 during mid-day trading on Friday, reaching $1.53. 108,827 shares of the company traded hands, compared to its average volume of 147,942. The company has a fifty day moving average price of $1.72 and a 200-day moving average price of $1.40. NextCure has a 52-week low of $0.98 and a 52-week high of $2.57. The company has a market capitalization of $42.79 million, a P/E ratio of -0.67 and a beta of 0.54.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.02. As a group, analysts forecast that NextCure will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. bought a new stake in NextCure during the first quarter worth about $952,000. Cable Car Capital LLC purchased a new position in shares of NextCure during the 4th quarter valued at about $702,000. Marquette Asset Management LLC bought a new stake in NextCure in the 4th quarter worth approximately $66,000. Finally, Acuitas Investments LLC boosted its stake in NextCure by 30.0% in the fourth quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock worth $425,000 after buying an additional 85,982 shares in the last quarter. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.